MARKET

PAVM

PAVM

Pavmed
NASDAQ
2.140
-0.590
-21.61%
After Hours: 2.268 +0.128 +6.00% 18:14 03/28 EDT
OPEN
2.610
PREV CLOSE
2.730
HIGH
2.660
LOW
2.140
VOLUME
193.25K
TURNOVER
0
52 WEEK HIGH
9.36
52 WEEK LOW
1.600
MARKET CAP
19.63M
P/E (TTM)
-0.2335
1D
5D
1M
3M
1Y
5Y
BUZZ-U.S. STOCKS ON THE MOVE-Netflix, Reddit, Stoke Therapeutics
The Dow Jones Industrial Average was up 0.72% on Wednesday. Merck & Co hit record high as FDA approves therapy for rare lung condition. Reddit Inc up 46% in fifth day of trading. Netflix, Reddit, Stoke Therapeutics are among the day's top stocks.
Reuters · 1d ago
SMR, GCTS and GSIW among mid-day movers
On the Move SMR, GCTS and GSIW among mid-day movers. GCT Semiconductor Holding (GCTS) and iBio are among the biggest gainers in the SA market. SMR and GCSR among the largest losers.
Seeking Alpha · 1d ago
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
LuxUrban Hotels shares dipped 27.4% to $1.5523 on Wednesday. The company issued preliminary fourth-quarter revenue outlook below estimates. MariaDB plc shares climbed 70.4%. Lixte Biotechnology Holdings, Inc. Shares jumped 68.6% in mid-day session.
Benzinga · 1d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Stoke Therapeutics (NASDAQ:STOK) shares increased by 46.1% to $15.03 during Wednesday's regular session. The company's market cap stands at $671.1 million. Nutriband stock rose 24.33% as the company's Q4 earnings came out yesterday. Lixte Biotechnology and Ontrak also moved upwards.
Benzinga · 1d ago
New Strong Buy Stocks for March 27th
NASDAQ · 1d ago
PAVM Stock Earnings: PAVmed Beats EPS, Misses Revenue for Q4 2023
PAVmed reported earnings per share of -$1.33. The company reported revenue of $1.05 million. This was 0.10% worse than the analyst estimate for the company to report revenue of £1.08 million. PAVmed is down 2.7% after the market close.
Investorplace · 1d ago
PAVmed Non-GAAP EPS of -$1.33 beats by $0.47, revenue of $1.05M beats by $0.02M
Earnings News PAVmed Non-GAAP EPS of -$1.33 beats by $0.47, revenue of $1.05M beats by £0.02M. PAvmed had cash and cash equivalents of $19.6 million as of December 31, 2022.
Seeking Alpha · 2d ago
*PAVmed 4Q Adj Loss/Shr $1.33 >PAVM
Dow Jones · 2d ago
More
About PAVM
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.

Webull offers PAVmed Inc stock information, including NASDAQ: PAVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PAVM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PAVM stock methods without spending real money on the virtual paper trading platform.